Cited by 1,074CAR-T cell therapy researchImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.

Engineered T cells: the promise and challenges of cancer immunotherapy

Open access

Fesnak, Andrew D., June, Carl H., Levine, Bruce L.·2016·Nature Reviews Cancer

DOI 10.1038/nrc.2016.97PMC PMC5543811

Open this paper in CoChat — free account

Abstract

The immune system evolved to distinguish non-self from self to protect the organism. As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge. This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumour microenvironment. The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed. Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy. Recent clinical trials using T cells engineered to express chimeric antigen receptors (CARs) or engineered T cell receptors (TCRs) have produced stunning results in patients with relapsed or refractory haematological malignancies. In this Review we describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc.2016.97

Cites

251 of 251 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–251 of 251

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors
Doorduijn, E. M., Sluijter, M., Querido, B. J., Oliveira, C. C., Achour, A., OSSENDORP, F. A., van der Burg, S. H., & van Hall, T. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83671 · Cited by 82
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor
Attianese, G. M. P. G., Marin, V., Hoyos, V., Savoldo, B., Pizzitola, I., Tettamanti, S., Agostoni, V., Parma, M., Ponzoni, M., Bertilaccio, M. T. S., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311845 · Cited by 81
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
Choudhury, A., Derkow, K., Daneshmanesh, A. H., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08362.x · Cited by 80
Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
Schuster, S. J., Svoboda, J., Nasta, S. D., Porter, D., Chong, E. A., Landsburg, D. J., Mato, A. R., Lacey, S. F., Melenhorst, J. J., Chew, A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.183.183 · Cited by 79
Self-citation
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor
Singh, H., Moyes, J. S. E., Huls, M. H., & Cooper, L. J. N. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.69 · Cited by 77
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
Mihara, K., Bhattacharyya, J., Kitanaka, A., Yanagihara, K., Kubo, T., Takei, Y., Asaoku, H., Takihara, Y., & Kimura, A. (2011) · Leukemia · doi:10.1038/leu.2011.205 · Cited by 77
Diminished expression of CD19 in B‐cell lymphomas
Yang, W., Agrawal, N. N., Patel, J., et al. (2004) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20030 · Cited by 70
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
Ahmed, N. M., Brawley, V. S., Hegde, M. G., Bielamowicz, K., Wakefield, A., Ghazi, A., Ashoori, A., Diouf, O., Gerken, C. P., Landi, D. B., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o11 · Cited by 62
Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations
Deniger, D. C., Yu, J., Huls, M. H., Figliola, M. J., Mi, T., Maiti, S. N., Widhopf, G. F., Hurton, L. V., Thokala, R., Singh, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128151 · Cited by 56
Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.
Beatty, G. L., O’Hara, M. H., Nelson, A. M., McGarvey, M., Torigian, D. A., Lacey, S. F., Melenhorst, J. J., Levine, B. L., Plesa, G., & June, C. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3007 · Cited by 55
Self-citation
The transpososome: control of transposition at the level of catalysis
Gueguen, E., Rousseau, P., Duval-Valentin, G., et al. (2005) · Trends in Microbiology · doi:10.1016/j.tim.2005.09.002 · Cited by 54
Kappa-Chain Deficiency
ZEGERS, B. J. M., Maertzdorf, W. J., van Loghem, E., et al. (1976) · New England Journal of Medicine · doi:10.1056/nejm197605062941902 · Cited by 52
Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program
Powell, D. J., Brennan, A. L., Zheng, Z., Huynh, H. A., Cotte, J., & Levine, B. L. (2009) · Cytotherapy · doi:10.3109/14653240903188921 · Cited by 51
Self-citation
Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia
Lee, D. W., Stetler‐Stevenson, M., Yuan, C. M., Fry, T. J., Shah, N. N., Delbrook, C., Yates, B., Zhang, H., Zhang, L., Kochenderfer, J. N., et al. (2015) · Blood · doi:10.1182/blood.v126.23.684.684 · Cited by 51
ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis
Lazzari, L., Gentile, A., Benvenuti, S., et al. (2013) · BMC Proceedings · doi:10.1186/1753-6561-7-s2-p43 · Cited by 50
Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Veomett, N. J., Dao, T., Liu, H., Xiang, J., Pankov, D., Dubrovsky, L., Whitten, J. A., Park, S., Korontsvit, T., Zakhaleva, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2756 · Cited by 50
Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL
Park, J. H., Rivière, I., Wang, X., et al. (2015) · Blood · doi:10.1182/blood.v126.23.682.682 · Cited by 48
Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature
Zhu, X., & Verma, S. (2015) · Current Oncology · doi:10.3747/co.22.2363 · Cited by 44
Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).
Frey, N. V., Shaw, P. A., Hexner, E. O., Gill, S. I., Marcucci, K. T., Luger, S. M., Mangan, J. K., Grupp, S. A., Maude, S. L., Ericson, S. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7002 · Cited by 42
Self-citation
Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma
Rizk, N. P., Servais, E. L., Tang, L. H., Sima, C. S., Gerdes, H., Fleisher, M., Rusch, V. W., & Adusumilli, P. S. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0993 · Cited by 40
Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses
Saret, C. J., Winn, A. N., Shah, G. L., Parsons, S. K., Lin, P., Cohen, J. T., & Neumann, P. J. (2015) · Blood · doi:10.1182/blood-2014-07-592832 · Cited by 39
Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas.
Schuster, S. J., Svoboda, J., Nasta, S. D., Porter, D. L., Mato, A. R., Shah, G., Landsburg, D. J., Chong, E. A., Lacey, S. F., Melenhorst, J. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8516 · Cited by 39
Self-citation
Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL).
Sauter, C. S., Riviere, I., Bernal, Y., Wang, X., Purdon, T., Yoo, S., Moskowitz, C. H., Giralt, S., Matasar, M. J., Curran, K. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8515 · Cited by 36
Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.
O’Rourke, D. M., Nasrallah, M. P., Morrissette, J. J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2067 · Cited by 33
Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
Maude, S. L., Barrett, D. M., Ambrose, D. E., et al. (2015) · Blood · doi:10.1182/blood.v126.23.683.683 · Cited by 29
Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers
Tanyi, J. L., Haas, A. R., Beatty, G. L., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct105 · Cited by 23
Prolonged functional persistence of CD19CAR t cell products of defined CD4:CD8 composition and transgene expression determines durability of MRD-negative ALL remission.
Gardner, R., Finney, O. C., Smithers, H. M., Leger, K. J., Annesley, C., Summers, C. N., Lindgren, C. G., Mgebroff, S., Brown, C., Spratt, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3048 · Cited by 15
Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.18_suppl.lba3010 · Cited by 14
Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia
Ren, J., Liu, X., Fang, C., et al. (2015) · Blood · doi:10.1182/blood.v126.23.4280.4280 · Cited by 14
Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma.
Garfall, A. L., Maus, M. V., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., Dengel, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8517 · Cited by 14
Self-citation
Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature
Khattab, M. H., Marciscano, A. E. E., Lo, S. S.-M., et al. (2015) · Case Reports in Oncological Medicine · doi:10.1155/2015/431819 · Cited by 12
A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers
Lu, Y., Parker, L. L., Lu, T., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p158 · Cited by 12
ATL treatment: is it time to change?
Hermine, O. (2015) · Blood · doi:10.1182/blood-2015-10-670489 · Cited by 12
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia
Efficace, F., Mandelli, F., Platzbecker, U., Cottone, F., & Lo‐Coco, F. (2015) · Blood · doi:10.1182/blood-2015-07-658922 · Cited by 12
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
Gaultney, J. G., Redekop, K., Sonneveld, P., & Groot, C. A. U. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.42 · Cited by 10
Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies
Ruella, M., Barrett, D. M., Kenderian, S. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.2523.2523 · Cited by 10
Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL
Curran, K. J., Rivière, I., Silverman, L. B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.2533.2533 · Cited by 10
Ex vivo replicative potential of adult human peripheral blood CD4+ T cells
Levine, B. L., Bernstein, W., Craighead, N., et al. (1997) · Transplantation Proceedings · doi:10.1016/s0041-1345(97)00216-9 · Cited by 9
Self-citation
Applications of Sleeping Beauty transposons for nonviral gene therapy
Liu, H., & Visner, G. A. (2007) · IUBMB Life · doi:10.1080/15216540701435722 · Cited by 9
Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chávez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Navale, L., Aycock, J. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.3991.3991 · Cited by 9
415. First-In-Patient Proof of Safety and Efficacy of a 4th Generation Chimeric Antigen Receptor-Modified T Cells for the Treatment of Relapsed or Refractory CD30 Positive Lymphomas
Ying, Z., Chang, L., Kuo, H.-H., et al. (2015) · Molecular Therapy · doi:10.1016/s1525-0016(16)34024-2 · Cited by 9
A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma
Hegde, M. G., Grada, Z., Pignata, A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o3 · Cited by 8
Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells.
Slovin, S. F., Wang, X., Bórquez-Ojeda, O., Stefanski, J., Olszewska, M., Taylor, C., Bartido, S. M., Scher, H. I., Sadelain, M., & Rivière, I. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps4700 · Cited by 8
CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT
Curran, K. J., Kernan, N. A., Wang, X., et al. (2012) · Blood · doi:10.1182/blood.v120.21.353.353 · Cited by 7
A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).
Porter, D. L., Frey, N. V., Loren, A. W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.tps7132 · Cited by 6
30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015).
(2015) · PubMed · Cited by 6
Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin's lymphoma: an open-label phase 1 trial
Wang, C., Wu, Z., Wang, Y., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00590-5 · Cited by 5
Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.lba3010 · Cited by 4
Abstract A041: CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia – report from the Swedish phase I/IIa trial
Enblad, G., Karlsson, H., Wikstrom, K. I., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr15-a041 · Cited by 3
First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial
Evans, M., Guest, R. D., Rothwell, D. G., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-s3-p12 · Cited by 2
T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo.
Regan, C., Clark, J. I., Moore, T. V., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3043 · Cited by 1

Flagged first, then by citations

Sorted by citations

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Self-citation
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616

See all 1,074

Authors: Fesnak, A. D., June, C. H., & Levine, B. L.
Affiliations: University of Pennsylvania (US)
Corresponding author: Fesnak, Andrew D.
Levine, Bruce L.
ORCID: Fesnak, Andrew D.
June, Carl H.
Levine, Bruce L.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2016-08-23
Volume: 16
Issue: 9
Pages: 566-581
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc.2016.97
PMC: PMC5543811
OpenAlex: W2515679023
Cited by: 1,074
References: 251
Citations by year: 2026: 55 · 2025: 76 · 2024: 73 · 2023: 71 · 2022: 91 · 2021: 144 · 2020: 134 · 2019: 127 · 2018: 161 · 2017: 122 · 2016: 13
FWCI: 14.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Parker Foundation
Leukemia and Lymphoma Society
National Institutes of Health
National Heart, Lung, and Blood Institute (T32HL007775)
National Cancer Institute (R01CA165206, R01CA120409, P30CA016520)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: engineered T cells, adoptive cell transfer, cancer immunotherapy, chimeric antigen receptor, engineered T cell receptors, B-cell malignancies, hematologic malignancies, solid tumors, tumor immune evasion, tumor microenvironment, immune tolerance
MeSH terms: Gene Editing, Antigens, Neoplasm, Clinical Trials as Topic, Forecasting, Genetic Engineering, HLA Antigens, Humans, Neoplasms, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, Syndrome, T-Lymphocyte Subsets, Cytokines, Immunotherapy, Adoptive, Antigen Presentation, Gene Transfer Techniques, Models, Immunological, Antigens, CD19, Tumor Escape, Hematologic Neoplasms, T-Cell Antigen Receptor Specificity, Tumor Microenvironment, Costimulatory and Inhibitory T-Cell Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Engineered T cells: the promise and challenges of cancer immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks